Programmed Mast Cell Hyperreactivity Syndrome
A heritable, underdiagnosed terrain at the intersection of multiple chronic conditions — whose underlying unity siloed medicine has yet to fully recognize.
The Programmed Mast Cell Hyperreactivity Syndrome (PMCHS) designates a heritable biological terrain in which mast cells — sentinel cells of the immune system — exhibit a chronically lowered activation threshold. This dysregulation is programmed: it results from the interaction between genetic predisposition, perinatal stress exposure, and epigenetic amplifiers transmissible across generations.
Unlike mast cell activation syndromes (MCAS) as currently defined, PMCHS presents not as an isolated pathology but as a transversal mechanism — a common underlying denominator across conditions as diverse as lipedema, PCOS, sudden infant death syndrome, autism spectrum disorders, ADHD, PTSD, fibromyalgia, and long COVID.
The term"idiopathic" — without known cause — no longer reflects what scientific and epidemiological data consistently shows. PMCHS proposes a coherent mechanistic framework where specialized medicine still sees only silos.
Predominantly transmitted along the maternal line, consistent with an epigenetic profile. Maternal-to-paternal ratio of 5.4:1 in survey data (N=423).
ERα/GPR30 → mast cell activation → histamine + LTC4 → endothelial HMGB1 → mast cell activation via RAGE. A self-sustaining cycle that amplifies the terrain over time.
Early stress and childhood trauma dysregulate the HPA axis and durably lower the mast cell reactivity threshold via NR3C1 methylation — programming the terrain for decades ahead.
The same underlying terrain expresses itself differently depending on target organs: adipose, vascular, neurological, reproductive — explaining chronic multi-system symptomatology.
In PMCHS, chronic excess histamine progressively desensitises H1 receptors in the hypothalamus — the central organ that integrates all the body's homeostatic signals. The result: a functional blindness to internal signals, independent of willpower and invisible on standard clinical examination.
The same hypothalamic pulsatile logic applies to the somatotropic axis: GHRH, like TRH, depends on intact hypothalamic signaling for its nocturnal pulsatile secretion. Chronic H1 desensitization could therefore also blunt GH secretion and, consequently, IGF-1 — potentially resulting in slowed growth or adult height slightly below genetic potential. This remains a non-systematic hypothesis, to be confirmed with cohort data (height, childhood growth velocity).
This is not a primary neurological disorder. It is the same mechanism by which any receptor chronically exposed to its ligand eventually reduces its sensitivity — adaptive down-regulation with concrete consequences on daily life.
The good news: under mast cell stabilisation (quercetin, luteolin, cromoglycate), progressive re-sensitisation of hypothalamic H1 receptors is possible. The return of functional satiety after treating the underlying terrain constitutes one of the first clinical validations of this hypothesis.
⚗️ Original hypothesis — mechanistic components published (Goldstein & Halperin 1977; Li et al. 2025), application to PMCHS terrain: E. Silva 2026. Formal documentation in progress.